U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
BETHESDA, Md., April 04, 2017 -- India Globalization Capital Inc. (NYSE MKT:IGC) announces that on April 3, 2017, it received a NYSE MKT LLC notice indicating that the Company has fallen below certain NYSE MKT continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on March 31, 2016, as set forth in Section 704 of the Company Guide.
To regain compliance, the Company will hold the annual meeting promptly after filing its Form 10-K for fiscal year ended March 31, 2017, which is due by June 30, 2017, following the submission of a plan in form prescribed by the NYSE MKT LLC by April 10, 2017.
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life-altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward-looking statements as discussed in detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Contact Info: Claudia Grimaldi 301-983-0998
